Browse All

Current Filters

CLEAR FILTER x

TITLE

Effect of Longer-term Ofatumumab Treatment on Disability Progression and Brain Volume Change

Author:Cohen, Jeffrey   Hauser, Stephen   Zielman, Ronald   Das Gupta, Ayan   Azmon, Amin   Xi, Jing   Mavrikis Cox, Gina   Robertson, Derrick   Wiendl, Heinz   Kappos, Ludwig   

Session Name:S16: MS Clinical Trials and Therapeutics  

Topic:MS and Inflammatory Disease  

Program Number:S16.009  

Author Institution:Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  UCSF Weill Institute for Neurosciences, Department of Neurology, University of California - San Francisco, San Francisco, CA, USA, San Francisco, CA  Central Texas Neurology Consultants, Round Rock, TX, USA, Round Rock, TX  Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharma A.G., Basel, Switzerland, Basel, Switzerland  China Novartis Institutes for BioMedical Research Co., Ltd, Shanghai, China, Shanghai, China, People's Republic of  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL, USA, Tampa, FL  University of Muenster, Muenster, Germany, Muenster, Germany  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  

Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS

Author:Alvarez, Enrique   Kuhle, Jens   Kappos, Ludwig   Ziemssen, Tjalf   Arnold, Douglas   Cross, Anne   Boer, Ibolya   Das Gupta, Ayan   Hu, Xixi   Kukkaro, Petra   Kieseier, Bernd   Zielman, Ronald   Hauser, Stephen   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.013  

Author Institution:Department of Neurology, Rocky Mountain MS Center at the University of Colorado, Aurora, CO  Neurology, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland  Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl Gustav Carus, Dresden, Germany  McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University and NeuroRx Research, Montreal, QC, Canada  Washington University School of Medicine, Saint Louis, MO  Novartis Pharma AG, Basel, Switzerland  Novartis Healthcare, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma B.V., Amsterdam, Netherlands  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA  

Efficacy of Early Ofatumumab vs Late Switch From Teriflunomide: Subgroup Analysis of the ALITHIOS Open-label Extension Study by Previous Disease-Modifying Therapy Exposure and Age

Author:Wiendl, Heinz   Cohen, Jeffrey   Gold, Ralf   De Seze, Jerome   Robertson, Derrick   Wray, Sibyl   Sacca, Francesco   Zielman, Ronald   Azmon, Amin   King, Miriam   Fantaccini, Simone   Kappos, Ludwig   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.016  

Author Institution:University of Muenster, Muenster, Germany  Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH  Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany  University Hospital of Strasbourg, Strasbourg, France  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL  Hope Neurology MS Center, Knoxville, TN  Department (NSRO), University “Federico II” of Naples, Naples, Italy  Novartis Pharma B.V., Amsterdam, Netherlands  Novartis Pharma AG, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland  

Compliance and Persistence With Ofatumumab Treatment in Patients With Relapsing Multiple Sclerosis in Clinical Trials for Up to 4 Years

Author:Alvarez, Enrique   Hersh, Carrie   Robertson, Derrick   Das Gupta, Ayan   Hu, Xixi   Zielman, Ronald   Boer, Ibolya   Cheadle, Andy   Cohen, Jeffrey   

Session Name:P8: MS Therapeutics 2  

Topic:MS and Inflammatory Disease  

Program Number:P8.002  

Author Institution:Department of Neurology, Rocky Mountain Multiple Sclerosis Center at the University of Colorado , Aurora, CO  Lou Ruvo Center for Brain Health, Cleveland Clinic Mellen Program for MS, Las Vegas, NV  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL  Novartis Healthcare, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma B.V., Amsterdam, Netherlands  Novartis Pharma AG, Basel, Switzerland  Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH  

Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis

Author:Cohen, Jeffrey   Hauser, Stephen   Cross, Anne   Winthrop, Kevin   Wiendl, Heinz   Nicholas, Jacqueline   Meuth, Sven   Giacomini, Paul   Sacca, Francesco   Zielman, Ronald   Das Gupta, Ayan   Hu, Xixi   Sullivan, Roseanne   DeLasHeras, Virginia   Kappos, Ludwig   

Session Name:P8: MS Therapeutics 2  

Topic:MS and Inflammatory Disease  

Program Number:P8.004  

Author Institution:Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA  Washington University School of Medicine, Saint Louis, MO, USA, Clayton, MO  Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR, USA, Portland, OR  University of Muenster, Muenster, Germany, Muenster, Germany  OhioHealth Multiple Sclerosis Center, Columbus, OH, USA, Columbus, OH  Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, Duesseldorf, Germany  Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada  NSRO Department, University “Federico II” of Naples, Naples, Italy, Napoli, Italy  Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Morristown, NJ  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland